Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 2.45 USD 3.81% Market Closed
Market Cap: 138m USD

Net Margin

-108.1%
Current
Declining
by 56.9%
vs 3-y average of -51.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-108.1%
=
Net Income
$-43.8m
/
Revenue
$40.5m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-108.1%
=
Net Income
$-43.8m
/
Revenue
$40.5m

Peer Comparison

Country Company Market Cap Net
Margin
US
Spero Therapeutics Inc
NASDAQ:SPRO
138m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.5B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 85% of companies in the United States of America
Percentile
15th
Based on 15 072 companies
15th percentile
-108.1%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Spero Therapeutics Inc
Glance View

Market Cap
138m USD
Industry
Biotechnology

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

SPRO Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-108.1%
=
Net Income
$-43.8m
/
Revenue
$40.5m
What is Spero Therapeutics Inc's current Net Margin?

The current Net Margin for Spero Therapeutics Inc is -108.1%, which is below its 3-year median of -51.2%.

How has Net Margin changed over time?

Over the last 3 years, Spero Therapeutics Inc’s Net Margin has increased from -1 162.7% to -108.1%. During this period, it reached a low of -1 162.7% on Aug 30, 2022 and a high of 22% on Dec 31, 2023.

Back to Top